Objectives: To find out occurrence of ovarian hyperstimulation in patients who were hyper responders in in vitro fertilization cycles. Secondary outcome was to assess number of metaphase II oocyte and fertilization rate, cleavage rate and pregnancy outcome when GnRHa is used for final maturation and triggering ovulation.
STUDY DESIGN, SIZE, and DURATION: This is retrospective descriptive analysis of cases managed at single center from June 2017 till May 2018.
PATIENTS & METHODS: Twenty patients were identified as hyper responders based on baseline, ovarian reserve characteristics, that is antral follicle count, (AFC) > 25, AMH > 4ng/ml and on day of trigger, follicles >-25 in number of ≥ 11mm were administered GnRHa trigger and 1500IU hCG on oocyte retrieval day while luteal phase was supported with daily vaginal progesterone and twice daily estradiol valerate. Sixteen patients underwent fresh transfer while four patients had their embryos frozen.
MAIN RESULTS: Twenty patients were identified as high risk and their baseline characteristics were, mean age 31.7 ± 4.50, mean antral follicle count 25.7 ± 5.01, Anti Mullerian hormone level mean 4.64 ± 2.52 and PCOS was present in 35% cases. Peak estradiol level mean 13455-± 6632pmol/l and mean follicles count of 25.45 ± 8.78 confirmed a high response. Oocyte yield was 11.45+ Metaphase oocyte retrieved were 85.5% and cleavage rate of 93%. No case of early onset OHSS was identified. Only one patient developed moderate OHSS. Pregnancy rate was 31.25%. Miscarriage rate was 6.3% and ongoing pregnancy was 25%.
CONCLUSION: This small retrospective descriptive analysis supports the view of current literature that GnRH trigger not only prevents early onset OHSS also achieves increase of M11 oocytes. In addition, pregnancy outcome is not statistically different to those cycles where hCG is used as trigger.
Schwartz M, Jewelewicz R. .The use of gonadotrophins for induction of ovulation. Fertil Steril.1981;5:3-12
Yen S.S.C, Lenera G, et al Disappearance rate of endogenous luteinizing hormone and chorionic gonadotropin in max. J.Clin. Endocrinol. Metab 1968;28:1763---1767
Kumer Ne, Feinn Rs, Griffen DW et al. Predicting successful induction of oocyte maturation after gonadotrophin releasing hormone agonist GnRH trigger. Hum Reprod 2013;28:152-9
Gonan Y, Balakier H, Powell W, Casper RF Use of gonadotrophin- releasing hormone agonist to trigger follicular maturation for in vitro fertilization Clin Endocrinol Metab. 2002;5:232-9
Humaidan P’. Luteal Phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low dose hCG: a pilot study. Reprod Biomed online 2009; 18: 630-634
Radesic B, Tremellen k. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Human Reproduction 2011; 26: 3437-42
Humaidan P, Ejdrup BH, Westergoard LG, Y ding AC. 1500 IU of human chorionic gonadotrophin administered at oocyte retrieval rescues the luteal phase when gonadotropin releasing hormone agonist is used for ovulation induction: a prospective, randomized controlled study. Fertil Steril 2010; 93: 847-854
NICE. Fertility; Assessment and treatment for people with fertility problems. London: National Institute for Health and Care Excellence, 2013
Golan A, Ron El, Herman A, et al.. Ovarian hyper stimulation syndrome: an update review obstet. Gynaecol. Surv.1989; 44: 43-440.
Wada I, Matson Pl, Troup SA et al., Does elective cryopreservation of all embryo from women at risk of ovarian hyper stimulation syndrome reduce the incidence of condition? Br. J. obstet. Gynaecol 1993; 100: 265-269
Imoedemhe DA, Sigue AB, Pacpaco EL. Stimulation of endogenous surge of luteinizing hormone with gonadotrophin releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril 1991; 55: 328-32
Humaidan P, Bredkjaer HE, Bungum L.2005 GnRH agonist or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles. A prospective randomized study. Hum Repord 2005; 20:1213-1220
Saijiao Li, Danni Zhou, Tailang Yin, Wangming Xu, Qingzhen Xie, Dancheng. Dual trigger of triptorelin and hCG optimizes clinical outcome for high responders in GnRH antagonist protocol. Impact journal 2018.
Munoz M, Cruz M, Humaidan P, et al., The type of GnRH analogue used during controlled ovarian stimulation influences early embryo development kinetics: a time – lapse study. Eur J obstet Gynaecol Reprod Biol 2013; 168: 167-172
Kolibianakis EM, Schultz – Mosgan A, Schroer A, Vansteirteghem A. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG in patients undergoing IVF with GnRH antagonist. Hum Reprod 2005; 20: 2887-2892
Itskovitz – Eldor J, Kol S, Mannaerts B. Use of single bolus of GnRH agonist triptorelin – Human Reproduction. 2000; 15: 1965-8
Engmann L, Benadiva C. Ovarian hyper stimulation syndrome prevention strategies: Luteal phase strategies to optimize pregnancy success in cycles with gonadotrophin releasing hormone agonist ovulatory trigger. Semin Reprod Med 2012; 28: 506-12
Griesinger G, Von Ott S, Schroer A et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective observational proof-of-concept study. Human Reproduction 2007; 22: 1348-1352
Seyhan A, Ata B, Polat M, Son WY. Yarali H. Dahan MH. Severe early ovarian hyper stimulation syndrome following GnRH antagonist trigger with the addition of 1500IU of hCG. Hum Reprod 2013; 28: 2522
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2023 Safia Sultana Munir, Misbah Sultana, Shazia Ashraf, Muhammad Khan